The world’s population is aging at an unprecedented pace. According to WHO’s October 2024 report, the number of people aged 60 and older surpassed children under five for the first time in 2020. By ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Keith Speights (AbbVie): AbbVie has been a longtime favorite for income investors. The big drugmaker's 52 consecutive years of dividend increases (including when it was part of Abbott) qualify it as a ...

AbbVie's combination antibiotic Emblaveo has gotten federal approval to treat complicated intra-abdominal infections, making it the first and only such therapy approved to fight antimicrobial ...

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Jim Cramer, the host of Mad Money, on Tuesday, took a close look at President Donald ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...

Shares of AbbVie Inc. (NYSE:ABBV) surged after the company reported strong Q4 2024 results and provided in-line revenue guidance and better-than-expected EPS guidance for 2025. I am very pleased ...

AbbVie provided an optimistic outlook for 2025, with an adjusted EPS guidance range of $12.12 to $12.32 and total net revenues expected to reach $59 billion. The company anticipates significant ...

AbbVie's Q4 EPS of $2.16 beat the forecast by $0.10. Revenue for the quarter was $15.1 billion, exceeding expectations. The stock price increased by 6.82% following the earnings release. Full-year ...